News & Events

• July 12, 2023
  

  Sanford Health Rare Disease Data Registry Partners with C-Path’s RDCA-DAP, Cure Mito Foundation to Aggregate Rare Disease Data in Platform

  C-Path announced today that the Coordination of Rare Diseases based at Sanford Research (CoRDS), in partnership with Cure MITO, will contribute its mitochondrial disorders data from its international patient registry to the C-Path-managed Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).

• July 6, 2023
  

  Multistakeholder Collaborations Are Vital to Advancing Technologies in Parkinson’s

  C-Path and the Center for Health + Technology (CHeT) at University of Rochester today announced the release of two seminal publications about digital health technologies for Parkinson’s. These technologies, such as smartphones and wearable sensors, offer an opportunity for objective, frequent and remote assessment of people with Parkinson’s.

• June 28, 2023
  

  C-Path’s TRxA Announces $750,000 in Research Awards to Accelerate its First Drug Development Projects

  C-Path Translational Therapeutics Accelerator (TRxA) announced today its first two research grants supporting academic scientists in advancing novel compounds through the drug development process. Launched in June 2022, TRxA is a global drug discovery and development program focused on supporting academic scientists in defining optimal strategies for advancing new, cutting-edge therapeutics, from the lab to patients.

• June 20, 2023
  

  C-Path’s Integrated Clinical Trial Database to Help Advance Research in Parkinson’s

  TUCSON, Ariz., June 20, 2023 — Critical Path Institute (C-Path), an independent nonprofit organization, today announced it is providing access to the Critical Path for Parkinson’s (CPP) Integrated Parkinson’s Database to external qualified researchers. With 10 million people living with Parkinson’s worldwide, the fastest growing degenerative neurological condition, collaboration and data sharing are crucial to......
• June 13, 2023
  

  C-Path’s PSTC Receives Positive FDA Response for Drug-Induced Pancreatic Injury Biomarkers

  C-Path today announced that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) in the U.S. Food and Drug Administration (FDA) issued a Biomarker Letter of Support (LOS) for four pancreatic injury safety biomarkers identified and evaluated by C-Path’s Predictive Safety Testing Consortium (PSTC)’s Pancreatic Injury Working Group (PIWG).